Higher anticholinergic burden from medications is associated with significant increase in markers of inflammation in the EPIC-Norfolk prospective population-based cohort study

Ria  Sanghavi; Tiberiu A.  Pana; Hulkar  Mamayusupova; Ian Maidment; Chris Fox; S Matthijs Boekholdt; Mamas A Mamas; Nicholas J. Wareham; Kay Tee Khaw; Phyo Kyaw Myint

doi:10.1111/bcp.15261

Higher anticholinergic burden from medications is associated with significant increase in markers of inflammation in the EPIC-Norfolk prospective population-based cohort study

Ria Sanghavi, Tiberiu A. Pana, Hulkar Mamayusupova, Ian Maidment, Chris Fox, S Matthijs Boekholdt, Mamas A Mamas, Nicholas J. Wareham, Kay Tee Khaw, Phyo Kyaw Myint^* (Corresponding Author)

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

2 Downloads (Pure)

Abstract

Background: Higher medication anticholinergic burden is associated with increased risk of cardiovascular disease and cognitive decline. A mechanistic pathway has not been established. We aimed to determine whether inflammation may mediate these associations.
Methods: Participants were drawn from the European Prospective Investigation into Cancer, Norfolk cohort (40-79 years at baseline). Anticholinergic burden score (ACB) was calculated at first (1HC) (1993/97) and second (2HC) (1998/2000) health checks. Fibrinogen and Creactive protein (CRP) were measured during 1HC and Tumour Necrosis Factor alpha (TNFα) and interleukin 6 (IL-6) during 2HC. Cross-sectional associations between ACB and
inflammatory markers were examined for both health checks. Prospective associations were also examined between 1HC ACB and 2HC inflammatory markers. Models were adjusted for age, sex, lifestyle factors, co-morbidities and medications.
Results: 17,678 and 22,051 participants were included in cross-sectional analyses for CRP, and fibrinogen, respectively. 5,101 participants with data on TNF-α and IL-6 were included in the prospective analyses. Cross-sectionally, compared to ACB=0, ACB ≥4 was associated with higher fibrinogen, beta (95% confidence interval)=0.134 g/l (0.070, 0.199), CRP 1.175 mg/l (0.715, 1.634), IL-6 0.593 pg/ml (0.254, 0.932) and TNF-α 0.137 pg/ml (0.033, 0.241).
Furthermore, a point increase in ACB was associated with a higher levels of all markers.
Prospectively, compared to ACB=0, ACB ≥4 was associated with higher IL-6(pg/ml): 0.019 (-0.323, 0.361) and TNF-α(pg/ml): 0.202% (0.81, 0.323). In addition, a unit increase in ACB was associated with a significantly higher TNF-α and IL-6.
Conclusion: Higher ACB was associated with higher inflammatory markers. Inflammation may mediate the relationship between anticholinergic medications and adverse outcomes.

Original language	English
Pages (from-to)	3297-3306
Number of pages	10
Journal	British Journal of Clinical Pharmacology
Volume	88
Issue number	7
Early online date	27 Feb 2022
DOIs	https://doi.org/10.1111/bcp.15261
Publication status	Published - 1 Jul 2022

Bibliographical note

Acknowledgements:
We are grateful to all the participants who have been part of the project and to the many members of the study teams at the University of Cambridge who have enabled this research. We would also like to acknowledge the principal investigators and staff of the EPIC-Norfolk study.
Funding
The EPIC-Norfolk study (DOI 10.22025/2019.10.105.00004) was funded by the Medical Research Council, Grant number (MR/N003284/1 and MC-UU_12015/1) and Cancer Research UK, Grant number (C864/A14136).

Data Availability Statement

Data available on request to EPIC-Norfolk Steering Committee for their approval.

Keywords

Anticholinergics
fibrinogen
C-Reactive Protein
Tumour Necrosis Factor-alpha
Interleukin-6
cardiovascular diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/bcp.15261Licence: CC BY

Sanghavi_etal_Higher_anticholinergic_burden_VOR
https://creativecommons.org/licenses/by/4.0/
Final published version, 1.3 MBLicence: CC BY

Cite this

Sanghavi, R., Pana, T. A., Mamayusupova, H., Maidment, I., Fox, C., Boekholdt, S. M., Mamas, M. A., Wareham, N. J., Khaw, K. T., & Myint, P. K. (2022). Higher anticholinergic burden from medications is associated with significant increase in markers of inflammation in the EPIC-Norfolk prospective population-based cohort study. British Journal of Clinical Pharmacology, 88(7), 3297-3306. https://doi.org/10.1111/bcp.15261

Higher anticholinergic burden from medications is associated with significant increase in markers of inflammation in the EPIC-Norfolk prospective population-based cohort study. / Sanghavi, Ria ; Pana, Tiberiu A. ; Mamayusupova, Hulkar et al.
In: British Journal of Clinical Pharmacology, Vol. 88, No. 7, 01.07.2022, p. 3297-3306.

Research output: Contribution to journal › Article › peer-review

Sanghavi, R, Pana, TA, Mamayusupova, H, Maidment, I, Fox, C, Boekholdt, SM, Mamas, MA, Wareham, NJ, Khaw, KT & Myint, PK 2022, 'Higher anticholinergic burden from medications is associated with significant increase in markers of inflammation in the EPIC-Norfolk prospective population-based cohort study', British Journal of Clinical Pharmacology, vol. 88, no. 7, pp. 3297-3306. https://doi.org/10.1111/bcp.15261

@article{ab23a5c2d7774b1089e3f69edc0bf4f3,

title = "Higher anticholinergic burden from medications is associated with significant increase in markers of inflammation in the EPIC-Norfolk prospective population-based cohort study",

abstract = "Background: Higher medication anticholinergic burden is associated with increased risk of cardiovascular disease and cognitive decline. A mechanistic pathway has not been established. We aimed to determine whether inflammation may mediate these associations.Methods: Participants were drawn from the European Prospective Investigation into Cancer, Norfolk cohort (40-79 years at baseline). Anticholinergic burden score (ACB) was calculated at first (1HC) (1993/97) and second (2HC) (1998/2000) health checks. Fibrinogen and Creactive protein (CRP) were measured during 1HC and Tumour Necrosis Factor alpha (TNFα) and interleukin 6 (IL-6) during 2HC. Cross-sectional associations between ACB andinflammatory markers were examined for both health checks. Prospective associations were also examined between 1HC ACB and 2HC inflammatory markers. Models were adjusted for age, sex, lifestyle factors, co-morbidities and medications.Results: 17,678 and 22,051 participants were included in cross-sectional analyses for CRP, and fibrinogen, respectively. 5,101 participants with data on TNF-α and IL-6 were included in the prospective analyses. Cross-sectionally, compared to ACB=0, ACB ≥4 was associated with higher fibrinogen, beta (95% confidence interval)=0.134 g/l (0.070, 0.199), CRP 1.175 mg/l (0.715, 1.634), IL-6 0.593 pg/ml (0.254, 0.932) and TNF-α 0.137 pg/ml (0.033, 0.241).Furthermore, a point increase in ACB was associated with a higher levels of all markers.Prospectively, compared to ACB=0, ACB ≥4 was associated with higher IL-6(pg/ml): 0.019 (-0.323, 0.361) and TNF-α(pg/ml): 0.202% (0.81, 0.323). In addition, a unit increase in ACB was associated with a significantly higher TNF-α and IL-6.Conclusion: Higher ACB was associated with higher inflammatory markers. Inflammation may mediate the relationship between anticholinergic medications and adverse outcomes. ",

keywords = "Anticholinergics, fibrinogen, C-Reactive Protein, Tumour Necrosis Factor-alpha, Interleukin-6, cardiovascular diseases",

author = "Ria Sanghavi and Pana, {Tiberiu A.} and Hulkar Mamayusupova and Ian Maidment and Chris Fox and Boekholdt, {S Matthijs} and Mamas, {Mamas A} and Wareham, {Nicholas J.} and Khaw, {Kay Tee} and Myint, {Phyo Kyaw}",

note = "Acknowledgements: We are grateful to all the participants who have been part of the project and to the many members of the study teams at the University of Cambridge who have enabled this research. We would also like to acknowledge the principal investigators and staff of the EPIC-Norfolk study. Funding The EPIC-Norfolk study (DOI 10.22025/2019.10.105.00004) was funded by the Medical Research Council, Grant number (MR/N003284/1 and MC-UU_12015/1) and Cancer Research UK, Grant number (C864/A14136).",

year = "2022",

month = jul,

day = "1",

doi = "10.1111/bcp.15261",

language = "English",

volume = "88",

pages = "3297--3306",

journal = "British Journal of Clinical Pharmacology",

issn = "0306-5251",

publisher = "Wiley-Blackwell ",

number = "7",

}

TY - JOUR

T1 - Higher anticholinergic burden from medications is associated with significant increase in markers of inflammation in the EPIC-Norfolk prospective population-based cohort study

AU - Sanghavi, Ria

AU - Pana, Tiberiu A.

AU - Mamayusupova, Hulkar

AU - Maidment, Ian

AU - Fox, Chris

AU - Boekholdt, S Matthijs

AU - Mamas, Mamas A

AU - Wareham, Nicholas J.

AU - Khaw, Kay Tee

AU - Myint, Phyo Kyaw

N1 - Acknowledgements: We are grateful to all the participants who have been part of the project and to the many members of the study teams at the University of Cambridge who have enabled this research. We would also like to acknowledge the principal investigators and staff of the EPIC-Norfolk study. Funding The EPIC-Norfolk study (DOI 10.22025/2019.10.105.00004) was funded by the Medical Research Council, Grant number (MR/N003284/1 and MC-UU_12015/1) and Cancer Research UK, Grant number (C864/A14136).

PY - 2022/7/1

Y1 - 2022/7/1

N2 - Background: Higher medication anticholinergic burden is associated with increased risk of cardiovascular disease and cognitive decline. A mechanistic pathway has not been established. We aimed to determine whether inflammation may mediate these associations.Methods: Participants were drawn from the European Prospective Investigation into Cancer, Norfolk cohort (40-79 years at baseline). Anticholinergic burden score (ACB) was calculated at first (1HC) (1993/97) and second (2HC) (1998/2000) health checks. Fibrinogen and Creactive protein (CRP) were measured during 1HC and Tumour Necrosis Factor alpha (TNFα) and interleukin 6 (IL-6) during 2HC. Cross-sectional associations between ACB andinflammatory markers were examined for both health checks. Prospective associations were also examined between 1HC ACB and 2HC inflammatory markers. Models were adjusted for age, sex, lifestyle factors, co-morbidities and medications.Results: 17,678 and 22,051 participants were included in cross-sectional analyses for CRP, and fibrinogen, respectively. 5,101 participants with data on TNF-α and IL-6 were included in the prospective analyses. Cross-sectionally, compared to ACB=0, ACB ≥4 was associated with higher fibrinogen, beta (95% confidence interval)=0.134 g/l (0.070, 0.199), CRP 1.175 mg/l (0.715, 1.634), IL-6 0.593 pg/ml (0.254, 0.932) and TNF-α 0.137 pg/ml (0.033, 0.241).Furthermore, a point increase in ACB was associated with a higher levels of all markers.Prospectively, compared to ACB=0, ACB ≥4 was associated with higher IL-6(pg/ml): 0.019 (-0.323, 0.361) and TNF-α(pg/ml): 0.202% (0.81, 0.323). In addition, a unit increase in ACB was associated with a significantly higher TNF-α and IL-6.Conclusion: Higher ACB was associated with higher inflammatory markers. Inflammation may mediate the relationship between anticholinergic medications and adverse outcomes.

AB - Background: Higher medication anticholinergic burden is associated with increased risk of cardiovascular disease and cognitive decline. A mechanistic pathway has not been established. We aimed to determine whether inflammation may mediate these associations.Methods: Participants were drawn from the European Prospective Investigation into Cancer, Norfolk cohort (40-79 years at baseline). Anticholinergic burden score (ACB) was calculated at first (1HC) (1993/97) and second (2HC) (1998/2000) health checks. Fibrinogen and Creactive protein (CRP) were measured during 1HC and Tumour Necrosis Factor alpha (TNFα) and interleukin 6 (IL-6) during 2HC. Cross-sectional associations between ACB andinflammatory markers were examined for both health checks. Prospective associations were also examined between 1HC ACB and 2HC inflammatory markers. Models were adjusted for age, sex, lifestyle factors, co-morbidities and medications.Results: 17,678 and 22,051 participants were included in cross-sectional analyses for CRP, and fibrinogen, respectively. 5,101 participants with data on TNF-α and IL-6 were included in the prospective analyses. Cross-sectionally, compared to ACB=0, ACB ≥4 was associated with higher fibrinogen, beta (95% confidence interval)=0.134 g/l (0.070, 0.199), CRP 1.175 mg/l (0.715, 1.634), IL-6 0.593 pg/ml (0.254, 0.932) and TNF-α 0.137 pg/ml (0.033, 0.241).Furthermore, a point increase in ACB was associated with a higher levels of all markers.Prospectively, compared to ACB=0, ACB ≥4 was associated with higher IL-6(pg/ml): 0.019 (-0.323, 0.361) and TNF-α(pg/ml): 0.202% (0.81, 0.323). In addition, a unit increase in ACB was associated with a significantly higher TNF-α and IL-6.Conclusion: Higher ACB was associated with higher inflammatory markers. Inflammation may mediate the relationship between anticholinergic medications and adverse outcomes.

KW - Anticholinergics

KW - fibrinogen

KW - C-Reactive Protein

KW - Tumour Necrosis Factor-alpha

KW - Interleukin-6

KW - cardiovascular diseases

U2 - 10.1111/bcp.15261

DO - 10.1111/bcp.15261

M3 - Article

C2 - 35118716

SN - 0306-5251

VL - 88

SP - 3297

EP - 3306

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

IS - 7

ER -

Higher anticholinergic burden from medications is associated with significant increase in markers of inflammation in the EPIC-Norfolk prospective population-based cohort study

Abstract

Bibliographical note

Data Availability Statement

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this